Stockreport

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights [Canadian Business Journal (Canada)]

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to rep [Read more]